Literature DB >> 16297532

Role of copper transporters in the uptake and efflux of platinum containing drugs.

Roohangiz Safaei1.   

Abstract

Cellular mechanisms for the uptake, intracellular distribution and efflux of the platinum (Pt) containing compounds cisplatin (DDP), carboplatin (CBDCA) and oxaliplatin (LOHP) are unknown. Current data suggest that specialized transporters/carriers mediate the transport of Pt drugs across the cellular membranes. Specific roles for the copper (Cu) transporters CTR1, ATP7A and ATP7B have been demonstrated during recent years. The finding that in cultured cells and tumor samples a correlation can be found between the expression of Cu transporters and the degree of the acquired resistance to Pt drug suggests that the Cu transporters are important constituents of the program that regulates sensitivity to Pt drugs. A model is presented that describes the function of Cu transporters in the regulation of Pt drug uptake and efflux.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297532     DOI: 10.1016/j.canlet.2005.07.046

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  44 in total

1.  The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.

Authors:  Xiang-Ping Li; Ji-Ye Yin; Ying Wang; Hui He; Xi Li; Wei-Jing Gong; Juan Chen; Chen-Yue Qian; Yi Zheng; Fang Li; Tao Yin; Zhi-Cheng Gong; Bo-Ting Zhou; Yu Zhang; Ling Xiao; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Tumour Biol       Date:  2014-05-23

2.  The effect of silver ions on copper metabolism and expression of genes encoding copper transport proteins in rat liver.

Authors:  S A Klotchenko; N V Tsymbalenko; K V Solov'ev; A N Skvortsov; E A Zatulovskii; P S Babich; N A Platonova; M M Shavlovskii; L V Puchkova; M Broggini
Journal:  Dokl Biochem Biophys       Date:  2008 Jan-Feb       Impact factor: 0.788

3.  Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.

Authors:  Katherine S Lovejoy; Stephen J Lippard
Journal:  Dalton Trans       Date:  2009-10-01       Impact factor: 4.390

4.  Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.

Authors:  J-H Deng; J Deng; D-H Shi; X-N Ouyang; P-G Niu
Journal:  Clin Transl Oncol       Date:  2015-06-02       Impact factor: 3.405

5.  Contribution of intracellular ATP to cisplatin resistance of tumor cells.

Authors:  Verena Schneider; Michaela L Krieger; Gerd Bendas; Ulrich Jaehde; Ganna V Kalayda
Journal:  J Biol Inorg Chem       Date:  2012-11-25       Impact factor: 3.358

Review 6.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12

7.  Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.

Authors:  Karoline Leonhardt; Rolf Gebhardt; Joachim Mössner; Svetlana Lutsenko; Dominik Huster
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

8.  Role of copper transporters in resistance to platinating agents.

Authors:  Cara A Rabik; Edward B Maryon; Kristen Kasza; John T Shafer; Catherine M Bartnik; M Eileen Dolan
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-08       Impact factor: 3.333

9.  Tryptophan scanning analysis of the membrane domain of CTR-copper transporters.

Authors:  Christopher J De Feo; Sara Mootien; Vinzenz M Unger
Journal:  J Membr Biol       Date:  2010-03-12       Impact factor: 1.843

10.  Expression of Na,K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin.

Authors:  Ramakumar Tummala; Daniel Wolle; Sonali P Barwe; Valerie B Sampson; Ayyappan K Rajasekaran; Lakshmi Pendyala
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-26       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.